ReviewCurrent opinion in organ transplantation2011
Stem cell-derived islet cells for transplantation.
Review in Current opinion in organ transplantation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Establishment and characterization of a novel human induced pluripotent stem cell line stably expressing the iRFP720 reporter.Scientific reports · 2022Article
- Differential Function and Maturation of Human Stem Cell-Derived Islets After Transplantation.Stem cells translational medicine · 2022Article
- Article
- Small Molecule-Induced Pancreatic β-Like Cell Development: Mechanistic Approaches and Available Strategies.International journal of molecular sciences · 2020Review
- Recent advances in organoid culture for insulin production and diabetes therapy: methods and challenges.BMB reports · 2019Review
- Generation of pancreatic β cells for treatment of diabetes: advances and challenges.Stem cell research & therapy · 2018Review
- Acute Ischemia Induced by High-Density Culture Increases Cytokine Expression and Diminishes the Function and Viability of Highly Purified Human Islets of Langerhans.Transplantation · 2017Article
- Considerations on the harvesting site and donor derivation for mesenchymal stem cells-based strategies for diabetes.CellR4-- repair, replacement, regeneration, & reprogramming · 2017Article
- Bone marrow derived stem cell therapy for type 2 diabetes mellitus.Stem cell investigation · 2016Article
- Enhancement of the propagation of human embryonic stem cells by modifications in the gel architecture of PMEDSAH polymer coatings.Biomaterials · 2014Article
- Polycomb group protein expression during differentiation of human embryonic stem cells into pancreatic lineage in vitro.BMC cell biology · 2014Article
- Influence of in vitro and in vivo oxygen modulation on β cell differentiation from human embryonic stem cells.Stem cells translational medicine · 2014Article
- A cost-minimization analysis of tissue-engineered constructs for corneal endothelial transplantation.PloS one · 2014Article
- Concise review: clinical programs of stem cell therapies for liver and pancreas.Stem cells (Dayton, Ohio) · 2013Review
- A scalable system for production of functional pancreatic progenitors from human embryonic stem cells.PloS one · 2012Article
- β-Cell Generation: Can Rodent Studies Be Translated to Humans?Journal of transplantation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewThe promise of islet transplantation for type 1 diabetes has been hampered by the lack of a renewable source of insulin-producing cells. However, steadfast advances in the field have set the stage for stem cell-based approaches to take over in the near future. This review focuses on the most intriguing findings reported in recent years, which include not only progress in adult and embryonic stem cell differentiation, but also the direct reprogramming of nonendocrine tissues into insulin-producing beta cells. RECENT
findingsIn spite of their potential for tumorigenesis, human embryonic stem (hES) cells are poised to be in clinical trials within the next decade. This situation is mainly due to the preclinical success of a differentiation method that recapitulates beta cell development. In contrast, adult stem cells still need one such gold standard of differentiation, and progress is somewhat impeded by the lack of consensus on the best source. A concerted effort is necessary to bring their potential to clinical fruition. In the meantime, reported success in reprogramming might offer a 'third way' towards the rescue of pancreatic endocrine function. SUMMARY: Here we discuss the important strategic decisions that need to be made in order to maximize the therapeutic chances of each of the presented approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.